OMIC Stock Price, Singular Genomics Systems, . Quote, Chart

Market Summary

USD0.40-0.01

Delayedas of 25 Apr 2024, 02:37 pm

-2.44%

OMIC Stock Price

View Fullscreen

OMIC RSI Chart

OMIC Valuation

Market Cap

30.3M

Price/Earnings (Trailing)

-0.32

Price/Sales (Trailing)

3.04

Price/Free Cashflow

-0.41

OMIC Price/Sales (Trailing)

OMIC Profitability

Operating Margin

65.23%

Return on Equity

-52.97%

Return on Assets

-35.72%

Free Cashflow Yield

-246.17%

OMIC Fundamentals

OMIC Revenue

Revenue (TTM)

10.0M

Rev. Growth (Yr)

280.2%

Rev. Growth (Qtr)

1.3K%

OMIC Earnings

Earnings (TTM)

-94.8M

Earnings Growth (Yr)

-10.18%

Earnings Growth (Qtr)

-3.98%

Breaking Down OMIC Revenue

52 Week Range

0.361.21

(Low)(High)

Last 7 days

2.5%

Last 30 days

-18%

Last 90 days

-10.9%

Trailing 12 Months

-59%

How does OMIC drawdown profile look like?

OMIC Financial Health

Current Ratio

10.51

Debt/Equity

0.05

Debt/Cashflow

-8.27

OMIC Investor Care

Shares Dilution (1Y)

2.79%

Diluted EPS (TTM)

-1.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.1M	5.9M	5.3M	10.0M
2022	758.0K	773.0K	1.8M	3.4M
2021	531.3K	598.5K	665.8K	733.0K
2020	0	0	0	464.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Singular Genomics Systems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	ropp sam	acquired	-	-	4,187	chief commercial officer
Mar 15, 2024	spaventa andrew	gifted	-	-	-14,583	chief executive officer
Mar 15, 2024	spaventa andrew	acquired	-	-	14,583	chief executive officer
Mar 15, 2024	spaventa andrew	gifted	-	-	14,583	chief executive officer
Mar 15, 2024	glezer eli n.	acquired	-	-	7,500	chief scientific officer
Mar 15, 2024	meeter dalen	acquired	-	-	6,250	chief financial officer
Dec 15, 2023	meeter dalen	acquired	-	-	6,250	chief financial officer
Dec 15, 2023	glezer eli n.	acquired	-	-	7,500	chief scientific officer
Dec 15, 2023	spaventa andrew	gifted	-	-	14,583	chief executive officer
Dec 15, 2023	spaventa andrew	acquired	-	-	14,583	chief executive officer

Which funds bought or sold OMIC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Bay Rivers Group	sold off	-100	-6,441	-	-%
Apr 15, 2024	Palumbo Wealth Management LLC	new	-	6,453	6,453	-%
Apr 12, 2024	DLK Investment Management, LLC	unchanged	-	1,352	12,855	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-1.03	140,690	861,575	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	99.65	11,115	18,992	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	reduced	-10.00	78,198	978,583	0.02%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	13.00	79.00	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-4,944	-	-%
Feb 15, 2024	DAGCO, INC.	new	-	782	782	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	1,000	6,000	-%

Are Funds Buying or Selling OMIC?

Are funds buying OMIC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMIC

No. of Funds

Unveiling Singular Genomics Systems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	spaventa andrew	7.9%	5,958,096	SC 13G/A
Feb 14, 2024	glezer eli n.	6.6%	4,872,083	SC 13G/A
Feb 12, 2024	flynn james e	0.00%	0	SC 13G/A
Jan 25, 2024	domain partners ix, l.p.	5.1%	3,763,985	SC 13G/A
Aug 14, 2023	flynn james e	0.55%	401,784	SC 13G/A
Feb 14, 2023	revelation alpine, llc	1.7%	1,184,497	SC 13G/A
Feb 14, 2023	spaventa andrew	6.7%	4,873,307	SC 13G/A
Feb 14, 2023	glezer eli n.	6.0%	4,299,583	SC 13G/A
Feb 10, 2023	flynn james e	2.05%	1,466,000	SC 13G/A
Feb 14, 2022	revelation alpine, llc	6.9%	4,988,602	SC 13G

Recent SEC filings of Singular Genomics Systems, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 05, 2024	PRE 14A	PRE 14A
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 18, 2024	S-8	Employee Benefits Plan
Mar 18, 2024	10-K	Annual Report

Peers (Alternatives to Singular Genomics Systems, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.82%	-2.78%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-3.26%	-10.41%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-1.72%	-10.74%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.03%	-9.90%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	0.44%	-12.46%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-2.07%	18.57%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.49%	-36.41%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.85%	-24.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-3.04%	14.62%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-3.54%	-1.62%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-13.37%	-14.88%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	3.23%	-3.00%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	11.39%	-31.43%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	18.11%	-48.10%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-12.07%	240.00%	-0.33	1.07	5.77%	8.23%

Singular Genomics Systems, Inc. News

Latest updates

Singular Genomics Systems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	1276.0%	6,357	462	2,295	863	1,672	1,115	428	156	105	84.00	413	131	104	76.00	156
Cost Of Revenue	191.8%	1,538	527	597	807	789	-	-	-	-	-	-	-	-	-	-
Gross Profit	-603.1%	-457	-65.00	-92.00	56.00	-24.00	-	-	-	-	-	-	-	-	-	-
Operating Expenses	1.4%	24,824	24,474	27,511	25,434	22,506	24,694	24,243	22,020	19,673	17,461	13,883	10,262	-	7,778	6,768
S&GA Expenses	-0.9%	13,134	13,254	14,887	13,204	11,746	11,962	12,182	11,375	10,218	8,551	6,201	3,654	-	1,698	1,443
R&D Expenses	4.2%	11,690	11,220	12,624	12,230	10,761	12,732	12,061	10,645	9,455	8,910	7,682	6,608	-	6,080	5,325
Interest Expenses	0.7%	287	285	270	259	243	211	167	142	192	234	232	188	-	202	235
Net Income	-4.0%	-23,249	-22,360	-25,578	-23,633	-21,101	-23,790	-23,982	-22,006	-19,760	-17,611	-37,479	-23,921	-7,115	-7,933	-6,847
Net Income Margin	45.7%	-9.50*	-17.51*	-15.83*	-22.68*	-26.96*	-49.63*	-107.84*	-127.78*	-134.75*	-122.34*	-98.52*	-	-	-	-
Free Cashflow	-14.0%	-19,294	-16,923	-20,304	-18,096	-21,735	-22,913	-27,690	-20,778	-17,469	-12,597	-16,807	-9,692	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-6.7%	265	285	284	305	328	345	366	342	356	371	384	31.00
Current Assets	-8.8%	192	211	226	246	268	286	306	326	348	364	379	28.00
Cash Equivalents	-51.3%	16.00	33.00	75.00	129	74.00	95.00	155	190	202	240	258	12.00
Inventory	1.1%	14.00	13.00	14.00	17.00	18.00	17.00	12.00	6.00	3.00	-	-	-
Net PPE	2.0%	14.00	13.00	11.00	11.00	11.00	10.00	9.00	7.00	6.00	5.00	3.00	2.00
Liabilities	1.1%	86.00	85.00	66.00	65.00	68.00	69.00	69.00	25.00	19.00	19.00	17.00	13.00
Current Liabilities	18.3%	18.00	15.00	14.00	12.00	14.00	14.00	13.00	9.00	7.00	6.00	8.00	4.00
Long Term Debt	-12.5%	9.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	6.00	8.00
LT Debt, Current	-	1.00	-	-	-	-	-	-	-	-	-	3.00	1.00
LT Debt, Non Current	-12.5%	9.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	6.00	8.00
Shareholder's Equity	-10.1%	179	199	218	240	260	277	298	317	336	352	367	-
Retained Earnings	-7.4%	-337	-314	-292	-266	-242	-221	-197	-173	-151	-132	-114	-53.12
Additional Paid-In Capital	0.6%	516	514	511	507	504	500	496	492	488	484	481	2.00
Shares Outstanding	0.7%	74.00	73.00	73.00	72.00	72.00	71.00	71.00	71.00	72.00	39.00	22.00	11.00
Float	-	-	-	49.00	-	-	-	214	-	-	-	1,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-12.4%	-18,902	-16,813	-19,998	-17,934	-19,917	-21,786	-25,552	-19,839	-15,699	-10,976	-15,841	-9,185	-	-	-
Share Based Compensation	-3.8%	2,687	2,794	2,842	3,081	3,099	3,399	3,605	3,566	2,935	2,859	2,341	1,096	-	-	-
Cashflow From Investing	102.6%	651	-24,703	-35,086	72,945	171	-38,117	-10,006	8,386	-23,325	-5,709	-11,366	-90,461	-	-	-
Cashflow From Financing	-	72.00	-	618	6.00	750	27.00	101	23.00	810	-1,320	239,154	133,484	-	-	-
Buy Backs	-	6.00	-	6.00	7.00	-35.00	53.00	421	11.00	-	-	-	-	-	-	-

OMIC Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 2,911	$ 765
Cost of revenue	3,469	789
Gross margin	(558)	(24)
Operating expenses:
Research and development	47,764	46,199
Selling, General and Administrative	54,479	47,264
Total operating expenses	102,243	93,463
Loss from operations	(102,801)	(93,487)
Other income (expense):
Interest expense	(1,101)	(763)
Interest and other income	9,082	3,371
Total other income	7,981	2,608
Net loss	$ (94,820)	$ (90,879)
Earning per share, Diluted	$ (1.3)	$ (1.28)
Earnings per share, Basic	$ (1.3)	$ (1.28)
Weighted Average Number of Shares Outstanding, Diluted	72,796,250	71,148,076
Weighted Average Number of Shares Outstanding, Basic	72,796,250	71,148,076

OMIC Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 16,233	$ 74,266
Short-term investments	157,708	170,310
Accounts receivable	565	913
Inventory, net	13,572	18,221
Prepaid expenses and other current assets	4,150	4,722
Total current assets	192,228	268,432
Right-of-use lease assets	57,797	45,896
Property and equipment, net	13,692	10,784
Restricted cash	600	1,711
Other noncurrent assets	1,150	1,152
Total assets	265,467	327,975
Current liabilities:
Accounts payable	2,587	3,099
Accrued expenses	6,079	4,583
Lease liabilities, current	7,764	6,323
Other current liabilities	1,857	113
Total current liabilities	18,287	14,118
Lease liabilities, non current	58,623	42,456
Long-term debt, net of issuance costs	8,901	10,065
Other noncurrent liabilities	650	1,015
Total liabilities	86,461	67,654
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 400,000,000 shares authorized, 73,823,161 and 71,854,688 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	7	7
Additional paid-in capital	516,439	503,926
Accumulated other comprehensive gain (loss)	155	(837)
Accumulated deficit	(337,595)	(242,775)
Total stockholders' equity	179,006	260,321
Total liabilities and stockholders' equity	265,467	327,975
Series A Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Series A Common Stock Equivalent Convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 and no shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	$ 0	$ 0

About Singular Genomics Systems, Inc.

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

CEO	Mr. Andrew Spaventa
WEBSITE	https://singulargenomics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	269

Singular Genomics Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Singular Genomics Systems, Inc.? What does OMIC stand for in stocks?

OMIC is the stock ticker symbol of Singular Genomics Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Singular Genomics Systems, Inc. (OMIC)?

As of Wed Apr 24 2024, market cap of Singular Genomics Systems, Inc. is 30.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMIC stock?

You can check OMIC's fair value in chart for subscribers.

What is the fair value of OMIC stock?

You can check OMIC's fair value in chart for subscribers. The fair value of Singular Genomics Systems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Singular Genomics Systems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMIC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Singular Genomics Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether OMIC is over valued or under valued. Whether Singular Genomics Systems, Inc. is cheap or expensive depends on the assumptions which impact Singular Genomics Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMIC.

What is Singular Genomics Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, OMIC's PE ratio (Price to Earnings) is -0.32 and Price to Sales (PS) ratio is 3.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMIC PE ratio will change depending on the future growth rate expectations of investors.